Howard M. Sandler, MD

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

March 8th 2018

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Dr. Sandler on Chemotherapy Combination Regimens in Prostate Cancer

November 28th 2016

Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.

Dr. Sandler on Radiation Therapy for Prostate Cancer

May 21st 2013

Howard M. Sandler, MD, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

Dr. Sandler on Orteronel in High-Risk Prostate Cancer

May 1st 2013

Howard M. Sandler, MD, from the Cedars-Sinai Medical Center, describes his excitement over research into new agents that modulate the androgen axis in prostate cancer.

Dr. Sandler on the Unique Characteristics of Radium-223

March 27th 2013

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Dr. Sandler Describes the RTOG 9408 Trial Results

April 23rd 2012

Dr. Howard Sandler, from Cedars-Sinai Medical Center, Describes the RTOG 9408 Prostate Cancer Trial Results

Dr. Sandler on the Importance of Radiation Therapy

April 7th 2011

Hormonal and Radiation Therapy in Prostate Cancer

April 5th 2011

TAK-700 in Localized Prostate Cancer Clinical Trials

April 4th 2011

Dr. Howard Sandler from Cedars-Sinai Medical Center discusses the TAK-700 in Localized Prostate Cancer Clinical Trials

Dr. Sandler on Clinical Trials for Liase Inhibitors

March 31st 2011

Dr. Sandler on Guideline Compliant Care

March 30th 2011

Howard M. Sandler, MD, MS from Cedars-Sinai Medical Center, on Guideline Compliant Care

Dr. Sandler on Candidates for Liase Inhibitor Clinical Trials

March 29th 2011

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses candidates for liase inhibitor clinical trials.

Traditional LHRH Agonists Versus Newer Drugs

March 29th 2011

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, compares the efficacy of the mechanism of action for traditional LHRH agonists to newer androgen deprivation therapies